Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in China / NCT07590284
Starting soon Not applicable

Sonazoid CEUS for Early HCC Surveillance

NCT07590284 · tracked via the Priya Life Science China tracker
Sponsor
Tianjin Third Central Hospital
Phase
Not applicable
Started
2026-05-30
Last updated
2026-05-15

Condition(s) studied

Liver CirrhosisLiver Fibrosis

Investigational drug(s) / intervention(s)

Sonazoid CEUS

Sonazoid CEUS: Sonazoid CEUS examination

Study summary

This study is a multicenter, prospective study. In this study, enrolled subjects are cirrhotic patients of any etiology. The US and Sonazoid CEUS monitoring strategy was performed for cirrhotic patients: US and AFP joint with Sonazoid CEUS every 4 to 6 months, and combined CECT/CEMRI every 12 months.

Eligibility

Sex
ALL
Min age
18 Years
Max age
80 Years
Healthy volunteers
No
Inclusion Criteria: 1. Cirrhotic patients diagnosed clinically or radiologically due to any etiology (patients with cirrhosis due to congenital fibrosis and patients with cirrhosis due to vascular causes were excluded). 2. Age 18-80 years old. 3. Able to receive regular imaging, including US, CEUS, and CECT or CEMRI or EOB-MRI, according to the diagnostic and treatment procedures. 4. Obtained informed consent from the patient. Exclusion Criteria: 1. Patients with pathologic or enhanced imaging of established HCC who have not undergone curative treatment. 2. Patients with known hypersensitivity to enhanced imaging contrast agents. 3. Patients with severe cardiac, pulmonary or renal insufficiency that precludes CECT or CEMRI or EOB-MRI. 4. Lactating and pregnant women. 5. Those who are not suitable for enrollment as assessed by the investigator. 6. Patients with egg or egg-product allergy, or with severe right-to-left cardiac shunt or intrapulmonary shunt.

Primary outcome measure(s)

  • Detection rate — 3-year
    To compare the detection rate of Sonazoid CEUS and US for early HCC

Trial sites (1)

FacilityCityRegionStatus
Tianjin Third Central Hospital Tianjin Tianjin Municipality

Other trials for the same condition

Comparison of Underdilated Versus Standard TIPS in Preventing Variceal Rebleeding in Patients With Cirrhosis Recruiting
Daridorexant for Sleep Disturbance in Adults With Liver Cirrhosis Starting soon
MR Elastography for Assessing Liver Fibrosis in Chronic Hepatitis B Recruiting
A Prospective Cohort Study on the Epidemiological Investigation, Diagnosis, and Treatment of Hepatic Encephalopathy Starting soon
Clinical Efficacy and Survival Prediction Analysis of Transjugular Intrahepatic Portosystemic Shunt in Patients With Liver Cirrhosis Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07590284 on ClinicalTrials.gov ↗ ← All trials in China